Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
05/09/2026 24:09
BRIEF-Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen Sept 4 (Reuters) - Royalty Pharma PLC RPRX.O:
ROYALTY PHARMA ANNOUNCES UPDATE ON NOVARTIS’ PHASE 3 TOPLINE RESULTS FOR PELACARSEN
ROYALTY PHARMA - NOVARTIS PHASE 3 HORIZON TRIAL FOR PELACARSEN FAILS TO MEET PRIMARY ENDPOINT
ROYALTY PHARMA - EXPECTS TO RECOUP INVESTMENT AND EARN MODEST RETURN DESPITE PELACARSEN FAILURE
Source text: ID:nGNX9q42CV
Further company coverage: RPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant